<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Bronchospasm; Sympathomimetics: asthma; Beta2 agonists; Asthma: beta2 agonists; Salbutamol: asthma; Terbutaline: asthma; Asthma: exercise-induced; Formoterol; Salmeterol; Asthma: nocturnal; Indacaterol; Asthma: nocturnal" /><meta name="IX" content="Bronchospasm; Sympathomimetics: asthma; Beta2 agonists; Asthma: beta2 agonists; Salbutamol: asthma; Terbutaline: asthma; Asthma: exercise-induced; Formoterol; Salmeterol; Asthma: nocturnal; Indacaterol; Asthma: nocturnal" /><title>3.1.1.1 Selective beta2 agonists: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1734-selective-beta-2-agonists.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1734-selective-beta-2-agonists.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1734-selective-beta-2-agonists.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP1716-respiratory-system.htm">3 Respiratory system</a> &gt; <a href="PHP1717-bronchodilators.htm">3.1 Bronchodilators</a> &gt; <a href="PHP1733-adrenoceptor-agonists.htm">3.1.1 Adrenoceptor agonists</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1733-adrenoceptor-agonists.htm" title="Previous: 3.1.1 Adrenoceptor agonists">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1744-bambuterol-hydrochloride.htm" title="Next: BAMBUTEROL HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>3.1.1.1 </span>Selective beta<sub>2</sub> agonists</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int720-sympathomimetics-beta-2.htm">Sympathomimetics, Beta<sub>2</sub></a>).</p></div></div><p id="PHP1735">Selective beta<sub>2</sub> agonists produce bronchodilation. A short-acting beta<sub>2</sub> agonist is used for immediate relief of asthma symptoms while some long-acting beta<sub>2</sub> agonists are added to an inhaled corticosteroid in patients requiring prophylactic treatment.</p><div class="cI"><p>Management of Chronic Asthma table, see   <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a></p><p>Management of Acute Asthma table, see <a title="topic: MANAGEMENT OF ACUTE SEVERE ASTHMA IN GENERAL PRACTICE" href="PHP1729-management-of-acute-asthma.htm">Management of Acute Asthma table</a></p></div><div><h2>Short-acting beta<sub>2</sub> agonists</h2><p>Mild to moderate symptoms of asthma respond rapidly to the inhalation of a selective short-acting beta<sub>2</sub> agonist such as <strong>salbutamol</strong> or <strong>terbutaline</strong>. If beta<sub>2</sub> agonist inhalation is needed more often than twice a week, or if night-time symptoms occur at least once a week, or if the patient has suffered an exacerbation in the last 2 years, then prophylactic treatment should be considered using a stepped approach as outlined in the <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>.</p><p>A short-acting beta<sub>2</sub> agonist inhaled immediately before exertion reduces <em>exercise-induced asthma</em>; however, frequent exercise-induced asthma probably reflects poor overall control and calls for reassessment of asthma treatment.</p></div><div id="PHP1736"><h2>Long-acting beta<sub>2</sub> agonists</h2><p><strong>Formoterol</strong> (eformoterol) and <strong>salmeterol</strong> are longer-acting beta<sub>2</sub> agonists which are administered by inhalation. They should be used for asthma only in patients who regularly use an inhaled corticosteroid (see <a title="BNF:target-block: Long acting beta2 agonists (CHM advice)" href="PHP1734-selective-beta-2-agonists.htm#PHP1737">CHM advice</a> below). They have a role in the long-term control of chronic asthma (see <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>) and they can be useful in nocturnal asthma. Salmeterol should not be used for the relief of an asthma attack; it has a slower onset of action than salbutamol or terbutaline. Formoterol is licensed for short-term symptom relief and for the prevention of exercise-induced bronchospasm; its speed of onset of action is similar to that of salbutamol. </p><p>Combination inhalers that contain a long-acting beta<sub>2</sub> agonist and a corticosteroid (<a title="BNF:section: Corticosteroids" href="PHP1843-corticosteroids.htm">section 3.2</a>) ensure that long-acting beta<sub>2</sub> agonists are not used without concomitant corticosteroids, but reduce the flexibility to adjust the dose of each component.</p></div><div class="cI" id="PHP1737"><h3 class="cT">CHM advice</h3><p>To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting beta<sub>2</sub> agonists (formoterol and salmeterol) should:</p><ul><li><p>be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately;</p> </li><li><p>not be initiated in patients with rapidly deteriorating asthma;</p> </li><li><p>be introduced at a low dose and the effect properly monitored before considering dose increase;</p> </li><li><p>be discontinued in the absence of benefit;</p> </li><li><p>not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used;</p> </li><li><p>be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved.</p> </li></ul><p>A daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.</p><p>Patients should be advised to report any deterioration in symptoms following initiation of treatment with a long-acting beta<sub>2</sub> agonist, see <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>.</p></div><p><strong>Indacaterol</strong> is a long-acting beta<sub>2</sub> agonist licensed for chronic obstructive pulmonary disease; it is not indicated for the relief of acute bronchospasm.</p><div id="PHP1739"><h2>Inhalation</h2><p><em>Pressurised-metered dose inhalers</em> are an effective and convenient method of drug administration in mild to moderate asthma. A spacer device (<a title="monograph-family: Drug delivery devices" href="PHP1829-drug-delivery-devices.htm">section 3.1.5</a>) may improve drug delivery. At recommended inhaled doses, the duration of action of salbutamol and terbutaline is about 3 to 5 hours, and 12 hours for salmeterol and formoterol. The <strong>dose</strong>, the frequency, and the maximum number of inhalations in 24 hours of the beta<sub>2</sub> agonist should be <strong>stated explicitly</strong> to the patient. The patient should be advised to seek medical advice when the prescribed dose of beta<sub>2</sub> agonist fails to provide the usual degree of symptomatic relief because this usually indicates a worsening of the asthma and the patient may require a prophylactic drug such as an inhaled corticosteroid (see <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>).</p><p><em>Nebuliser (or respirator) solutions</em> of salbutamol and terbutaline are used for the treatment of severe acute asthma in hospital or in general practice. Patients with a severe attack of asthma should preferably have oxygen during nebulisation since beta<sub>2</sub> agonists can increase arterial hypoxaemia. For the use of nebulisers in chronic obstructive pulmonary disease, see <a title="monograph-family: Nebulisers" href="PHP1840-nebulisers.htm">section 3.1.5</a>. The dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution, see also <a title=" Peak flow meters, inhaler devices and nebulisers" href="PHP1825-peak-flow-meters-inhaler-devices-and-nebulisers.htm">section 3.1.5</a>.</p> </div><div><h2>Oral</h2><p>Oral preparations of beta<sub>2</sub> agonists may be used by patients who cannot manage the inhaled route. They are sometimes used for children and the elderly, but inhaled beta<sub>2</sub> agonists are more effective and have fewer side-effects. The longer-acting oral preparations, including bambuterol, may be of value in nocturnal asthma but they have a limited role and inhaled long-acting beta<sub>2</sub> agonists are usually preferred.</p></div><div><h2>Parenteral</h2><p>Salbutamol or terbutaline can be given intravenously for severe or life-threatening acute asthma; patients should be carefully monitored and the dose adjusted according to response and heart rate. The regular use of beta<sub>2</sub> agonists by the subcutaneous route is not recommended since the evidence of benefit is uncertain and it may be difficult to withdraw such treatment once started. Beta<sub>2</sub> agonists may also be given by intramuscular injection.</p></div><div><h2>Children</h2><p>Selective beta<sub>2</sub> agonists are useful even in children under the age of 18 months. They are most effective by the inhaled route; a pressurised metered-dose inhaler should be used with a spacer device in children under 5 years (see NICE guidance, <a title=" Peak flow meters, inhaler devices and nebulisers" href="PHP1825-peak-flow-meters-inhaler-devices-and-nebulisers.htm">section 3.1.5</a>). A beta<sub>2</sub> agonist may also be given by mouth but administration by inhalation is preferred; a long-acting inhaled beta<sub>2</sub> agonist may be used where appropriate (see <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a>). In severe attacks nebulisation using a selective beta<sub>2</sub> agonist or ipratropium is advisable (see also <a title="topic: MANAGEMENT OF CHRONIC ASTHMA IN ADULTS AND CHILDREN" href="PHP1728-management-of-chronic-asthma.htm">Management of Chronic Asthma table</a> and <a title="topic: MANAGEMENT OF ACUTE SEVERE ASTHMA IN GENERAL PRACTICE" href="PHP1729-management-of-acute-asthma.htm">Management of Acute Asthma table</a>).</p></div><div id="PHP1740"><h2>Cautions</h2><p>Beta<sub>2</sub> agonists should be used with caution in hyperthyroidism, cardiovascular disease, arrhythmias, susceptibility to QT-interval prolongation, and hypertension. Beta<sub>2</sub> agonists should be used with caution in diabetes—monitor blood glucose (risk of ketoacidosis, especially when beta<sub>2</sub> agonist given intravenously). <strong>Interactions:</strong> Appendix 1 (sympathomimetics, beta<sub>2</sub>).</p> <div><div class="cE"><h3 class="cT">Hypokalaemia</h3> <p class="cT" id="PHP1741">Potentially serious hypokalaemia may result from beta<sub>2</sub> agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.</p></div> </div></div><div id="PHP1743"><h2>Side-effects</h2><p>Side-effects of the beta<sub>2</sub> agonists include fine tremor (particularly in the hands), nervous tension, headache, muscle cramps, and palpitation. Other side-effects include tachycardia, arrhythmias, peripheral vasodilation, myocardial ischaemia, and disturbances of sleep and behaviour. Paradoxical bronchospasm (occasionally severe), urticaria, angioedema, hypotension, and collapse have also been reported. High doses of beta<sub>2</sub> agonists are associated with hypokalaemia (see Hypokalaemia above).</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP1744-bambuterol-hydrochloride"><a href="PHP1744-bambuterol-hydrochloride.htm" title="BAMBUTEROL HYDROCHLORIDE">BAMBUTEROL HYDROCHLORIDE</a></li><li id="_PHP1748-formoterol-fumarate"><a href="PHP1748-formoterol-fumarate.htm" title="FORMOTEROL FUMARATE">FORMOTEROL FUMARATE</a></li><li id="_PHP1754-indacaterol"><a href="PHP1754-indacaterol.htm" title="INDACATEROL">INDACATEROL</a></li><li id="_PHP1756-salbutamol"><a href="PHP1756-salbutamol.htm" title="SALBUTAMOL">SALBUTAMOL</a></li><li id="_PHP1771-salmeterol"><a href="PHP1771-salmeterol.htm" title="SALMETEROL">SALMETEROL</a></li><li id="_PHP1775-terbutaline-sulfate"><a href="PHP1775-terbutaline-sulfate.htm" title="TERBUTALINE SULFATE">TERBUTALINE SULFATE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1733-adrenoceptor-agonists.htm">Previous: 3.1.1 Adrenoceptor agonists</a> | <a class="top" href="PHP1734-selective-beta-2-agonists.htm#">Top</a> | <a accesskey="]" href="PHP1744-bambuterol-hydrochloride.htm">Next: BAMBUTEROL HYDROCHLORIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>